| 17.41 0.15 (0.87%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.59 | 1-year : | 24.05 |
| Resists | First : | 17.62 | Second : | 20.59 |
| Pivot price | 15.35  |
|||
| Supports | First : | 13.84 | Second : | 11.5 |
| MAs | MA(5) : | 16.54 |
MA(20) : | 14.97 |
| MA(100) : | 8.61 |
MA(250) : | 0 | |
| MACD | MACD : | 1.4 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 94.9 |
D(3) : | 87.5 |
| RSI | RSI(14): 73.9 |
|||
| 52-week | High : | 17.62 | Low : | 3.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GLUE ] has closed below upper band by 9.9%. Bollinger Bands are 79% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 17.53 - 17.6 | 17.6 - 17.67 |
| Low: | 16.61 - 16.68 | 16.68 - 16.75 |
| Close: | 17.29 - 17.42 | 17.42 - 17.55 |
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Sat, 06 Dec 2025
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates - sharewise.com
Wed, 03 Dec 2025
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st
Mon, 01 Dec 2025
Improved Revenues Required Before Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock's 26% Jump Looks Justified - 富途牛牛
Sun, 30 Nov 2025
Monte Rosa: Looking Mispriced After Big Pharma Validation (NASDAQ:GLUE) - Seeking Alpha
Wed, 19 Nov 2025
Integrated Quantitative Investments LLC Acquires New Holdings in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Mon, 17 Nov 2025
22,500 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Bailard Inc. - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 105.5 (%) |
| Shares Short | 7,400 (K) |
| Shares Short P.Month | 8,080 (K) |
| EPS | 0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.98 |
| Profit Margin | 11.5 % |
| Operating Margin | -258.3 % |
| Return on Assets (ttm) | 1.3 % |
| Return on Equity (ttm) | 9.2 % |
| Qtrly Rev. Growth | 38.5 % |
| Gross Profit (p.s.) | 0.78 |
| Sales Per Share | 2.78 |
| EBITDA (p.s.) | 0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 149 (M) |
| Levered Free Cash Flow | 49 (M) |
| PE Ratio | 54.4 |
| PEG Ratio | 0 |
| Price to Book value | 4.37 |
| Price to Sales | 6.24 |
| Price to Cash Flow | 7.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|